Search
Tixagevimab
go.drugbank.com/drugs/DB16394ApprovedInvestigationalmay be exposed to the virus. … Tixagevimab, in combination with [cilgavimab], was issued an FDA emergency use authorization (EUA) on December 9, 2021, for the pre-exposure prophylaxis of COVID-19 in individuals at increased risk for
Categories: Antivirals for Systemic Use, Antiinfectives for Systemic UseOxethazaine
go.drugbank.com/drugs/DB12532ApprovedWithdrawn[A33104] Oxetacaine is approved by Health Canada since 1995 for its use as an antacid combination in over-the-counter preparations. … Oxetacaine, also called oxethazaince, is a potent surface analgesic with the molecular formula N, N-bis-(N-methyl-N-phenyl-t-butyl-acetamide)-beta-hydroxyethylamine that conserves its unionized form at low pH
Categories: Agents for Treatment of Hemorrhoids and Anal Fissures for Topical Use, Cytochrome P-450 CYP3A InhibitorsHypochlorous acid
go.drugbank.com/drugs/DB14135InvestigationalAn oxyacid of chlorine (HClO) containing monovalent chlorine that acts as an oxidizing or reducing agent.
Products: AN XIN Disinfectant, Disinfectant Solution for airNicoboxil
go.drugbank.com/drugs/DB12911ApprovedWithdrawnNicoboxil has been investigated for the treatment of Acute Low Back Pain, where it is typically considered an effective and safe therapeutic option. … and capability to be used as an alternative musculoskeletal pain therapy option with less systemic side effects when compared to the oral non-steroidal anti-inflammatory drugs and opioids that may be
Infigratinib
go.drugbank.com/drugs/DB11886ApprovedInvestigationalWithdrawn[A235174] On May 28, 2021, the FDA granted accelerated approval to infigratinib - under the market name Truseltiq - for the treatment of previously treated, unresectable locally advanced or metastatic … [L34304] The FDA later announced the final withdrawal of the approval of infigratinib for this indication on May 16, 2024: This decision was based on the sponsor's request due to clinical trial recruitment
Categories: Cytochrome P-450 Substrates, P-glycoprotein inhibitorsCitric acid
go.drugbank.com/drugs/DB04272ApprovedInvestigationalNutraceuticalVet approvedCitric acid is one of the active ingredients in Phexxi, a non-hormonal contraceptive agent that was approved by the FDA on May 2020. … It is an acid compound found in citrus fruits. The salts of citric acid (citrates) can be used as anticoagulants due to their calcium-chelating ability.
Mixtures: Urologic G for Irrigation, Urologic G for IrrigationCategories: Disinfectants (For Agents Used on Object)Cupric oxide
go.drugbank.com/drugs/DB11134ApprovedCupric oxide is used as a precursor in many copper-containing products such as wood preservatives and ceramics. … Cupric oxide may be found in over-the-counter vitamin-mineral supplements as a source of [DB09130]. The mean daily dietary intake of copper in adults ranges between 0.9 and 2.2 mg [L2422].
Mixtures: Complete Multivitamins and Minerals for Children, Virt-PnIcodextrin
go.drugbank.com/drugs/DB00702ApprovedInvestigationalIcodextrin is an iso-osmotic peritoneal dialysis solution containing glucose polymers. … It is used primarily for ambulatory peritoneal dialysis (CAPD) of diabetic patients and automated peritoneal dialysis (APD) for patients with end-stage renal disease.
Mupirocin
go.drugbank.com/drugs/DB00410ApprovedInvestigationalVet approvedProduced by fermentation using the organism _Pseudomonas fluorescens_, mupirocin is a naturally-occurring antibiotic that displays a broad-specturm activity against many gram-positive bacteria and certain
Categories: Antibiotics for Topical UseZolpidem
go.drugbank.com/drugs/DB00425ApprovedInvestigationalIt is aimed for use in patients with difficulties initiating sleep. … In addition, zolpidem improves sleep quality in patients suffering from chronic insomnia and can show mild muscle relaxant properties [L5584].
Mixtures: Sentrazolpidem PM-5Categories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP1A2 Substrates